恒瑞医药与默沙东就一款心血管创新药达成合作 交易金额最高19.7亿美元

每日经济新闻
25 Mar

3月25日,恒瑞医药公告称,公司与默沙东达成协议,将恒瑞医药的脂蛋白(a)[Lp(a)]口服小分子项目(包括名为HRS-5346的先导化合物)有偿许可给默沙东,默沙东将获得HRS-5346在大中华地区以外的全球范围内开发、生产和商业化的独家权利。根据美国相关法案,该许可协议需获得批准并满足其他特定交割条件后生效,预计生效时间为2025年第二季度。  根据协议条款,恒瑞医药将收取2亿美元的首付款,并...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10